坐骨神經痛市場規模、佔有率和成長分析（按疾病類型、藥物類別、給藥途徑、分銷管道和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，全球坐骨神經痛市場規模將達到 86.5 億美元，到 2025 年將成長至 91.4 億美元，到 2033 年將成長至 142.5 億美元，在預測期（2026-2033 年）內，複合年成長率為 5.7%。

由於久坐的生活方式、人口老化以及脊椎疾病發病率的上升等因素導致坐骨神經痛盛行率不斷增加，預計全球坐骨神經痛市場將顯著成長。診斷技術和治療方法的進步提高了坐骨神經痛診斷和治療策略的準確性。人們對早期療育和復原重要性的認知不斷提高，也進一步推動了市場發展。然而，治療成本上升、某些地區先進醫療設施匱乏以及手術可能帶來的併發症等挑戰可能會阻礙市場擴張。儘管如此，對微創手術的關注、新型治療方法的湧現以及對個人化治療方案日益成長的需求，預計將推動全球坐骨神經痛市場的成長。

全球坐骨神經痛市場促進因素

全球坐骨神經痛市場受到普遍缺乏對該疾病認知和漏診率高的影響。久坐的生活方式、不良姿勢、肥胖以及人口老化等因素導致坐骨神經痛的盛行率不斷上升。這導致人們對有效的診斷工具、各種治療方法和疼痛管理方案的需求日益成長。這一趨勢正在推動市場擴張，並凸顯了改善坐骨神經痛患者教育和治療方案的必要性，最終目標是改善患者的健康和生活品質。

全球坐骨神經痛市場的限制因素

全球坐骨神經痛市場面臨的一大挑戰是大眾對該疾病普遍缺乏了解，以及治療常常被忽視。許多坐骨神經痛患者未能識別自身症狀或尋求必要的醫療協助，導致診斷和治療延遲。此外，醫療服務資源匱乏，尤其是在農村地區，進一步加劇了這個問題，延緩了坐骨神經痛的有效治療。透過教育活動提高公眾意識，並改善醫療基礎設施，是緩解這項挑戰、最終改善坐骨神經痛患者診斷和治療效果的重要措施。

全球坐骨神經痛市場趨勢

全球坐骨神經痛治療市場的一個顯著趨勢是，微創治療方法越來越受到青睞，這反映了醫療保健領域向微創技術的轉變。內視鏡切除術和經皮減壓術等技術因其優於傳統手術的許多優勢而備受關注，這些優勢包括切口更小、組織損傷更少、恢復更快以及風險更低。這一趨勢主要源於患者對有效緩解疼痛且併發症更少的需求，以及醫療服務提供者對改善患者療效和降低成本的重視。因此，隨著患者和臨床醫生越來越接受這些創新治療方案，市場正經歷強勁成長。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 一手和二手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 技術評估
• 專利分析

全球坐骨神經痛市場規模（按疾病類型和複合年成長率分類）（2026-2033 年）

• 急性坐骨神經痛
• 慢性坐骨神經痛
• 其他

全球坐骨神經痛市場規模（按藥物類別和複合年成長率分類）（2026-2033 年）

• 非類固醇消炎劑
• 口服類固醇
• 抗驚厥藥
• 三環抗憂鬱藥物
• 鴉片類鎮痛藥
• 其他

全球坐骨神經痛市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 口服
• 注射

全球坐骨神經痛市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球坐骨神經痛市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • GCC
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

  主要企業簡介

  • 美敦力公司（愛爾蘭）
  • 強生公司（美國）
  • Zimmer Biomet Holdings, Inc.（美國）
  • 梯瓦製藥工業股份有限公司（以色列）
  • 賽諾菲公司（法國）
  • 諾華國際股份公司（瑞士）
  • 百時美施貴寶公司（美國）
  • 默克公司（美國）
  • Zynex公司（美國）
  • 索倫托治療公司（美國）
  • Hikma Pharmaceuticals PLC（英國）
  • Viatris公司（美國）
  • 波士頓科學公司（美國）
  • 雅培實驗室（美國）
  • 史賽克公司（美國）
  • 葛蘭素史克有限公司（英國）
  • 阿斯特捷利康有限公司（英國）
  • 禮來公司（美國）
  • 百時美施貴寶公司（美國）

結論與建議

Global Sciatica Market size was valued at USD 8.65 Billion in 2024 and is poised to grow from USD 9.14 Billion in 2025 to USD 14.25 Billion by 2033, growing at a CAGR of 5.7% during the forecast period (2026-2033).

Significant growth is anticipated in the global sciatica market, driven by the escalating prevalence of the condition, influenced by sedentary lifestyles, an aging population, and rising spinal disorders. Advancements in diagnostic technologies and treatment options enhance the accuracy of diagnoses and management strategies for sciatica. Increased awareness regarding the importance of early intervention and rehabilitation is further fueling market development. However, challenges such as high treatment costs, limited access to advanced healthcare facilities in certain areas, and potential surgical complications may hinder expansion. Nonetheless, the focus on minimally invasive procedures, the emergence of novel therapeutics, and the rising demand for personalized treatment approaches will likely propel the growth of the global sciatica market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sciatica market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sciatica Market Segments Analysis

Global Sciatica Market is segmented by Disease Type, Drug Class, Route of Administration, Distribution Channel and region. Based on Disease Type, the market is segmented into Acute Sciatica, Chronic Sciatica and Others. Based on Drug Class, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Oral Steroids, Anticonvulsant Agents, Tricyclic Antidepressants, Opioid Analgesics and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sciatica Market

The global sciatica market is significantly influenced by the widespread lack of awareness and frequent underdiagnosis of the condition. Contributing factors include sedentary lifestyles, poor posture, obesity, and an aging population, all of which lead to an increasing prevalence of sciatica. As a result, there is a growing demand for effective diagnostic tools as well as various therapies and pain management solutions. This trend fosters market expansion and highlights the necessity for improved education and treatment options for individuals affected by sciatica, ultimately enhancing overall health outcomes and quality of life for sufferers.

Restraints in the Global Sciatica Market

A significant challenge facing the global sciatica market is the general lack of awareness and frequent underdiagnosis of the condition. Numerous individuals experiencing sciatica may fail to identify their symptoms or may not pursue the necessary medical assistance, resulting in postponed diagnosis and treatment. Additionally, restricted access to healthcare services, particularly in rural regions, exacerbates the issue by delaying effective management of sciatica. Enhancing awareness through educational initiatives and improving healthcare infrastructure are essential steps that could alleviate this challenge, ultimately leading to better diagnosis and treatment outcomes for those affected by sciatica.

Market Trends of the Global Sciatica Market

A prominent trend in the global sciatica market is the rising preference for minimally invasive treatment options, reflecting a shift towards less invasive methodologies in healthcare. Techniques such as endoscopic discectomy and percutaneous decompression are gaining traction due to their numerous benefits, including reduced incision size, decreased tissue damage, quicker recovery times, and minimized risks compared to traditional surgical procedures. This trend is largely influenced by patient demand for effective pain relief with fewer complications, as well as healthcare providers' focus on enhancing patient outcomes and driving down costs. Consequently, the market is experiencing robust growth as both patients and clinicians increasingly embrace these innovative treatment solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Technology Assessment
• Patent Analysis

Global Sciatica Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Acute Sciatica
• Chronic Sciatica
• Others

Global Sciatica Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Nonsteroidal Anti-Inflammatory Drugs
• Oral Steroids
• Anticonvulsant Agents
• Tricyclic Antidepressants
• Opioid Analgesics
• Others

Global Sciatica Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Sciatica Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Sciatica Market Size & CAGR (2026-2033)

• North America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Class, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynex Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics, Inc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations